DBV Technologies to Highlight New Clinical Data at ACAAI

Montrouge, France, November 9, 2022

DBV Systems to Emphasize New Medical Facts at ACAAI 2022

DBV Systems (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a medical-stage biopharmaceutical company, nowadays announced that new scientific information on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers ages 1 to 3 several years will be introduced at the American School of Allergy, Asthma & Immunology (ACAAI) Once-a-year Scientific Assembly, which is staying held November 10-14, 2022, in Louisville, KY. Two abstracts have been acknowledged, such as a person oral presentation and one particular poster presentation. These presentations will be available on DBV’s internet site, www.dbv-systems.com, subsequent the summary of the assembly for all those who are not able to attend. DBV will also host a booth in the ACAAI Exhibit Hall from Friday, November 11, through Sunday, November 13.

This year’s conference will also feature a “Product Theater” on the Evolution of the Avoidance and Treatment of Peanut Allergy in Young Children. Professors Gideon Lack, M.D., and J. Andrew Chook, M.D., will interact in a energetic dialogue close to how evidence from peanut allergy prevention and treatment method experiments in younger youngsters might affect present and long run scientific practice. The Product Theater is scheduled for Saturday, November 12, from 9:35 a.m. to 10:00 a.m. EST in the Show Hall, Upper Concourse.

DBV is the sole sponsor, via an independent instructional grant, of the Intercontinental Foodstuff Allergy Symposium, a whole-day symposium that kicks off ACAAI. Leading experts from all over the world will existing different subjects associated to foods allergy, like epidemiology, diagnostics, avoidance and treatment method. The symposium is scheduled for Thursday, November 10, from 8:00 a.m. to 6:00 p.m. EST. The Company is also sponsoring the 31st Once-a-year Match Bowl, a video game show-type competitors that exams the know-how of taking part groups from instruction programs about the state. The levels of competition is established to be held on Saturday, November 12, from 5:30 p.m. to 7:30 p.m. EST in Commonwealth Ballroom Salons 1 & 2.

“There is a considerable unmet have to have that persists among the toddlers struggling from peanut allergy. The added facts getting offered at this year’s ACAAI assembly highlight the likely for Viaskin Peanut as a treatment choice for this young and susceptible client inhabitants if authorized,” explained Dr. Pharis Mohideen, Chief Health-related Officer of DBV Systems. “We go on to perform in the direction of trying to get approval to bring this novel treatment method solution to market as expeditiously as probable.”

Viaskin Peanut is the Company’s direct product or service prospect made to lower the hazard of allergic reactions because of to accidental publicity to peanuts. An investigational, non-invasive, as soon as-every day epicutaneous patch, Viaskin Peanut seeks to produce microgram portions of peanut antigen to re-teach the immune process. The basic safety and efficacy of Viaskin Peanut have not however been established by the U.S. Meals and Drug Administration or the European Medications Agency. Viaskin is DBV’s proprietary tactic to epicutaneous immunotherapy (EPIT™), a approach of providing biologically active compounds to the immune system via the skin.

DBV Abstracts:

Oral Presentation

“EPITOPE Study Success: Period 3, Randomized, Double-blind, Placebo-controlled Examine of Epicutaneous Immunotherapy in Peanut-allergic Toddlers” will be offered by Matthew Greenhawt, M.D., M.Sc., MBA, FACAAI, Children’s Healthcare facility Colorado, Aurora, CO.

Presentation ID: D019
Session Title: Distinguished Marketplace Oral Abstracts – Session B
Presentation Date: Saturday, November 12
Presentation Time: 4:30 p.m. – 5:30 p.m. EST
Presentation Spot: Place M104 – M107

Poster Presentation

“Reduction in Response Severity Pursuing 12 Months of Epicutaneous Immunotherapy with Peanut Patch in Toddlers” will be offered by Terri Brown-Whitehorn, M.D., Children’s Healthcare facility of Philadelphia, Philadelphia, PA.

Presentation ID: P183
Session Title: ePoster – Satisfy the Author
Presentation Date: Friday, November 11
Presentation Time: 3:00 p.m. EST
Presentation Place: Show Hall (Upper Concourse), Observe 16

About DBV Technologies
DBV Technologies is acquiring Viaskin™, an investigational proprietary technological innovation system with broad opportunity purposes in immunotherapy. Viaskin is primarily based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ system of offering biologically lively compounds to the immune procedure via intact skin. With this new course of non-invasive item candidates, the Company is devoted to safely reworking the treatment of foodstuff allergic people. DBV Technologies’ food items allergic reactions systems include things like ongoing medical trials of Viaskin Peanut. DBV Systems has world-wide headquarters in Montrouge, France, and North American functions in Basking Ridge, NJ. The Company’s regular shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (every single symbolizing a single-50 {18fa003f91e59da06650ea58ab756635467abbb80a253ef708fe12b10efb8add} of one particular ordinary share) are traded on the Nasdaq Worldwide Choose Market place (Ticker: DBVT).

Forward Seeking Statements
This push launch could comprise forward-searching statements and estimates, including statements with regards to the therapeutic potential of Viaskin™ Peanut as a cure for peanut-allergic youngsters and the prospective positive aspects of EPIT™. These ahead-on the lookout statements and estimates are not claims or assures and require substantial risks and uncertainties and may well be impacted by market place disorders as perfectly as other challenges and uncertainties established forth in DBV Technologies’ regulatory filings with the Autorité des Marchés Financiers (“AMF”), DBV Technologies’ filings and reports with the U.S. Securities and Trade Fee (“SEC”), and future filings and reviews built with the AMF and SEC. Present and potential investors are cautioned not to position undue reliance on these forward-hunting statements and estimates, which converse only as of the day hereof. Other than as expected by relevant legislation, DBV Systems undertakes no obligation to update or revise the facts contained in this Push Release.

Investor Call
Anne Pollak
DBV Technologies
+1 857-529-2363
[email protected]

Media Make contact with
Angela Marcucci
DBV Systems
+1 646-842-2393
[email protected]

Viaskin and EPIT are logos of DBV Systems.